Aastrom Biosciences, Inc. (NASDAQ: ASTM)

Aastrom Biosciences, Inc. (NASDAQ: ASTM) is focused on the development of autologous cell products for the repair or regeneration of human tissue. The Company’s proprietary Tissue Repair Cell (TRC) technology utilizes a patient’s own cells to create products to treat an array of chronic diseases as well as serious injuries. Currently, Aastrom is conducting a Phase II clinical trial with dilated cardiomyopathy (DCM) patients (the IMPACT-DCM trial) and a Phase IIb clinical trial with critical limb ischemia patients (the RESTORE-CLI trial). For further information, visit the Company’s web site at www.aastrom.com.